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Neuroprotection of the hypoxic-
ischemic mouse brain by human 
CD117+CD90+CD105+ amniotic 
fluid stem cells
Michelangelo Corcelli1, Kate Hawkins1, Filipa Vlahova1, Avina Hunjan1, Kate Dowding1,  
Paolo De Coppi2, Anna L. David  1,3, Donald Peebles1, Pierre Gressens4, Henrik Hagberg4,5, 
Mariya Hristova1 & Pascale V. Guillot1
Human amniotic fluid contains two morphologically-distinct sub-populations of stem cells with 
regenerative potential, spindle-shaped (SS-hAFSCs) and round-shaped human amniotic fluid stem cells 
(RS-hAFSCs). However, it is unclear whether morphological differences correlate with functionality, 
and this lack of knowledge limits their translational applications. Here, we show that SS-hAFSCs and 
RS-hAFSCs differ in their neuro-protective ability, demonstrating that a single contralateral injection 
of SS-hAFSCs into hypoxic-ischemic P7 mice conferred a 47% reduction in hippocampal tissue loss and 
43–45% reduction in TUNEL-positive cells in the hippocampus and striatum 48 hours after the insult, 
decreased microglial activation and TGFβ1 levels, and prevented demyelination. On the other hand, 
RS-hAFSCs failed to show such neuro-protective effects. It is possible that SS-hAFSCs exert their 
neuroprotection via endoglin-dependent inhibition of TGFβ1 signaling in target cells. These findings 
identify a sub-population of CD117+CD90+CD105+ stem cells as a promising source for the neuro-
protection of the developing brain.
Human fetal stem cells present a number of advantageous characteristics over their adult counterparts, such as 
faster growth kinetics, longer telomeres and higher differentiation potential1, thus presenting an intermediate 
phenotype between adult mesenchymal stem cells and embryonic stem cells2. Human amniotic fluid contains 
an alternative extraembryonic source of non-tumorigenic fetal stem cells that can be safely, ethically and read-
ily isolated during ongoing pregnancy from consenting women undergoing mid-trimester clinical amniocen-
tesis or from the fluid collected at time of delivery3. The regenerative potential of human amniotic fluid stem 
cells (hAFSCs)4 is further harnessed by their ability to give rise to multiple mesenchymal and non-mesenchymal 
lineages5 and their immunomodulatory properties6. However, the heterogeneity of the hAFSC population 
presents a hurdle for their therapeutic applications. Two distinct adherent cell types have previously been iso-
lated by Roubelakis et al. based on their morphological properties, and described as spindle-shaped (SS) 
and round-shaped (RS) hAFSCs, with SS-hAFSCs representing about 6% of the total hAFSC population and 
RS-hAFSCs 94%7. Comparative analysis revealing the higher proliferation rate, differentiation potential and in 
vitro migration ability of SS-hAFSCs7. However, their in vivo regenerative potential has not been systematically 
compared and most pre-clinical experiments have been performed using heterogeneous populations of hAFSCs.
To determine whether the morphological and phenotypical differences observed in vitro between SS-hAFSCs 
and RS-hAFSCs correlate with differential functionality, we compared the neuro-repair potential of the cells using 
the Vannucci mouse model of neonatal hypoxic ischaemic encephalopathy (HIE)8, whereby the left common 
carotid artery is permanently occluded and the mice exposed to a 60 min hypoxic challenge in 8% oxygen. HIE 
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is a major healthcare burden, being the fourth leading cause of childhood mortality and resulting in one million 
neuro-disabled children each year9,10. Whilst moderate hypothermia is now standard care, it is only partially 
effective and cannot be applied to pre-term babies11. With currently no effective cure addressing the underlying 
loss of cerebral tissue, there is an urgent need to develop a simple, safe and effective treatment to directly modu-
late pathophysiological processes and protect the developing brain of HIE-affected babies. Stem cell therapy has 
the potential to lessen brain injury either by replacing lost cells, promoting the differentiation of host progenitors, 
and/or modulating the host immune system12,13.
Here we show that, contrary to the results obtained with RS-hAFSCs, a single contralateral injection of 
SS-hAFSCs into the hypoxia-ischemia (HI) mouse brain contributed to lessening the size of the brain lesion, 
reduced the number of TUNEL+ cells, decreased microglial activation, prevented demyelination and reduced 
TGFβ1 levels. We are the first to demonstrate that SS-hAFSCs, which can easily be isolated from heterogeneous 
populations of hAFSCs based on their cell surface co-expression of CD105 and CD90, have potential for the 
protection of the developing brain.
Results
Differential cell surface molecule expression in SS-hAFSCs and RS-hAFSCs. The human mid-tri-
mester amniotic fluid contains a heterogeneous population of plastic-adherent cells presenting either a polymor-
phic round-shaped appearance (RS-hAFSCs) or an elongated spindle-shaped cytoplasm (SS-hAFSCs) (Fig. 1a,b). 
The cells studied here were karyotypically normal, isolated from the same gestational age (2 samples16 weeks 
and 3 days of gestation and 2 samples 16 weeks of gestation) and pooled from four different donors undergo-
ing prenatal diagnostic (healthy pregnancy) to reduce inter-individual variability. Both sub-populations were 
characterised by the positive expression of the stem cell marker CD117 in the cytoplasm (which is expressed on 
the cell surface of freshly isolated samples but gets internalised during ex vivo expansion) (Fig. 1b), the positive 
expression of the MSC marker CD73 and the negative expression of the hematopoietic markers CD34 and CD45 
(Fig. 1c). However, contrary to SS-hAFSCs, RS-hAFSCs do not express the cell surface markers CD90 (Thy-1) and 
CD105 (endoglin) (results obtained from 7 samples of SS-hAFSCs and 6 samples of RS-hAFSCs), indicating that 
these surface markers can also be used for purification of heterogeneous cell adherent CD117+ (C-Kit+) human 
amniotic fluid stem cell populations.
SS-hAFSCs, but not RS-hAFSCs, prevent lesion of the HI mouse hippocampus. To determine 
whether the differences in morphology and immunophenotype of SS-hAFSCs and RS-hAFSCs translate into 
differential regenerative functionality, we injected a single dose of 1 × 105 stem cells in 20 μl PBS in the con-
tralateral ventricle of P7 HI mice immediately after the HI insult, induced by the permanent ligation of the left 
carotid followed by exposure to 8% oxygen to induce hypoxic conditions. We compared the histology of the brain 
of HI mice injected with stem cells with those injected with PBS only (without stem cells) at 48 hours following 
HI insult. Histological analysis of the HI brain injected with PBS only revealed brain tissue loss compared to the 
control side in all the cerebral regions assessed (hippocampus, striatum, cortex, pyriform cortex, thalamus and 
external capsule) with the hippocampus being the structure with the largest lesion size (Fig. 2a), (uninjured con-
trol group in Supplementary Figure 1a). Injection of SS-hAFSCs led to a significant (47%) reduction in infarct size 
in the hippocampus (19.3 ± 3.2, n = 16) compared to HI mice injected with PBS alone (36.4 ± 4.8, mean ± SEM, 
n = 20; P = 0.00008 two-way ANOVA followed by Bonferroni’s multiple comparison test), but no difference was 
observed between PBS-injected mice and mice injected with SS-hAFSCs in the striatum (16.1 ± 3.6, n = 20 vs. 
15.1 ± 1.4; P = 0.99), cortex (11.6 ± 1.2, n = 20 vs. 9.8 ± 1.4, n = 16; P = 0.99), pyriform cortex (15.6 ± 1.5, n = 20 
vs. 13.1 ± 1.9, n = 16; P = 0.99), thalamus (9.8 ± 1.5, n = 20 vs. 8.7 ± 0.9, n = 16; P = 0.77) and external capsule 
(8.8 ± 1.3, n = 20 vs. 12.4 ± 1.4, n = 16; P = 0.99). Notably, no difference was observed between PBS-injected mice 
and mice injected with RS-hAFSCs in any of the brain regions tested, i.e. the hippocampus (32.7 ± 3.4, n = 16; 
P = 0.98), striatum (19.7 ± 2.1, n = 16; P = 0.99), cortex (13.6 ± 1.2, n = 16; P = 0.99), pyriform cortex (20.4 ± 2.3, 
n = 16; P = 0.99), thalamus (10.1 ± 2.6, n = 16; P = 0.99) and external capsule (7.2 ± 1.4, n = 16; P = 0.99).
Injection of SS-hAFSCs, but not RS-hAFSCs, decreases the number of TUNEL-positive cells in 
the hippocampus and striatum. Histological analysis of the HI brains injected with PBS only, showed that 
the HI insult resulted in the presence of TUNEL + staining of dying brain cells with fragmented DNA 48 hours 
later, with the hippocampus and striatum being the most affected regions (Fig. 2b), (uninjured control group in 
Supplementary Figure 1b). Compared to PBS-injected mice, the injection of SS-hAFSCs led to a 45% decrease 
of TUNEL + cells in the hippocampus (523.6 ± 55.1 mean ± SEM, n = 9 vs. 286.2 ± 39.7, n = 14; P = 0.007, 
two-way ANOVA followed by Bonferroni’s multiple comparison test) and to a 43% decrease in the striatum 
(470.3 ± 81.16, n = 9 vs. 268.2 ± 48.8, n = 14; P = 0.048), but not in the cortex (74.6 ± 18.3, n = 9 vs. 43.7 ± 14.5, 
n = 14; P = 0.99), pyriform cortex (98.11 ± 21.7, n = 8 vs.116.4 ± 27.2, n = 13; P = 0.99), thalamus (171.6 ± 52.2 
vs.124.6 ± 27.9, n = 14; P = 0.99) or external capsule (2.6 ± 0.4, n = 12 vs. 15.1 ± 2.3, n = 14; P = 0.99). Notably, 
injection of RS-hAFSCs had no significant positive effect on the hippocampus (451.3 ± 21.4, n = 15; P = 0.98), 
striatum (638.8 ± 95.7, n = 14; P = 0.14), cortex (89.6 ± 29.5, n = 16; P = 0.99), pyriform cortex (174.9 ± 50.6, 
n = 15; P = 0.97), thalamus (171.6 ± 52.2, n = 6; P = 0.99) and external capsule (2.6 ± 0.4, n = 12; P = 0.99).
Injection of SS-hAFSCs decreases microglial activation. To analyse the mechanistic role of donor 
stem cells, we assessed microglia activation by the expression of CD11b (αM) (Fig. 3a) and cell morphology 
(Fig. 3b), (uninjured control group in Supplementary Figure 1c). HI insult led 48 hours later to strong microglia 
activation. We showed that, in comparison to PBS-injected brains, injection of SS-hAFSCs significantly decreased 
CD11b expression in the hippocampus (3.2 ± 0.1, n = 20 vs. 2.4 ± 0.2, n = 16; P = 0.01, two-way ANOVA fol-
lowed by Bonferroni’s multiple comparison test), striatum (2.5 ± 0.2, n = 20 vs. 1.7 ± 0.2, n = 16; P = 0.03), 
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pyriform cortex (1.9 ± 0.2, n = 22 vs. 1.0 ± 0.2, n = 16; P = 0.01) and thalamus (2.1 ± 0.3, n = 22 vs. 0.9 ± 0.3, 
n = 16; P = 0.01), whilst injection of RS-hAFSCs only decreased CD11b in the pyriform cortex (1.9 ± 0.2, n = 22 
vs. 0.8 ± 0.2, n = 16; P = 0.01) (Fig. 3a). However, SS-hAFSCs injection had no effect on CD11b expression in 
the cortex (1.2 ± 0.1, n = 22 vs. 1.0 ± 0.2, n = 16; P = 0.06) and external capsule (2.9 ± 0.2 vs. 2.5 ± 0.3, n = 16; 
Figure 1. SS-hAFSCs and RS-hAFSCs differ for the expression of CD105 and CD90. (a) Isolation and 
representative inverted light microscopy images of human mid-trimester round-shaped (RS-hAFSCs) 
and spindle-shaped (SS-hAFSCs) amniotic fluid stem cells. (b) Example confocal immunostaining images 
demonstrating cytoplasmic CD117 staining (in green) in SS-hAFSCs and RS-hAFSCs counterstained with 
nuclear DAPI (blue). (c) Flow cytometry showing expression of CD73 and absence of expression of CD34 and 
CD45 in SS-hAFSCs and RS-hAFSCs, with only SS-hAFSCs expressing the cell surface markers CD90 and 
CD105. The red tracing shows the isotype control and the blue tracing shows the primary antibody.
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P = 0.98), whilst RS-hAFSC had no effect in the hippocampus (3.2 ± 0.1 vs. 3.0 ± 0.2, n = 15; P = 0.99), striatum 
(2.5 ± −0.2 vs. 1.9 ± 0.3, n = 14; P = 0.61), cortex (1.2 ± 0.1 vs. 0.8 ± 0.2, n = 16; P = 0.97), thalamus (2.1 ± 0.3, 
n = 22 vs. 2.0 ± 0.3, n = 15; P = 0.99) and external capsule (2.9 ± 0.2 vs. 2.7 ± 0.2, n = 16; P = 0.99) (Fig. 3a). We 
Figure 2. SS-hAFSCs decrease hippocampal lesion and number of dead cells in hippocampus and striatum.  
(a) Quantification of brain tissue volume loss in contralateral forebrain, assessed by Nissl staining (Cresyl-Violet), 
showing reduction of infarct size in the hippocampus of HI mice injected with SS-hAFSCs (mean ± SEM), 
***P < 0.001, * < 0.05. Representative images of Nissl-stained brain sections of HI mice injected with either PBS only, 
SS-hAFSCs or RS-hAFSCs. (b) TUNEL + staining showing reduced number of dying cells in HI brains injected with 
SS-hAFSCs. (mean ± SEM), **P < 0.01, *P < 0.05. Representative images (low and high magnification) of TUNEL-
stained brain sections of HI mice injected with either PBS only, SS-hAFSCs or RS-hAFSCs.
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observed more amoeboid or round morphology in the microglia of brains injected with either PBS alone or with 
RS-hAFSCs, compared to the ramified morphology14 in the brains injected with SS-hAFSCs (Fig. 3b).
Both SS-hAFSCs and RS-hAFSCs decrease reactive astrogliosis. Next, to investigate the impact 
of donor stem cells on reactive astrogliosis 48 h after injection, we determined the percentage of cells express-
ing GFAP (Fig. 4), (uninjured control group in Supplementary Figure 1d). Interestingly, both stem cell subsets 
significantly reduced GFAP immunoreactivity in all regions of the brain analysed. Compared to PBS-injected 
mice, those injected with either SS-hAFSCs or RS-hAFSCs decreased astroglial activation in the hippocampus 
(46.7 ± 2.4 mean ± SEM, n = 22 vs. 29.1 ± 2.6, n = 16 vs. 25.2 ± 2.6, n = 16; F(2.51) = 24.46, P = 0.00008, two-way 
ANOVA), striatum (34.5 ± 2.3, n = 22 vs. 16.3 ± 1.8, n = 16 vs. 20.8 ± 1.6, n = 16; F(2,51) = 22.58, P < 0.0001), 
cortex (26.4 ± 1.7, n = 22 vs. 13.4 ± 1.3, n = 16 vs. 15.4 ± 0.7, n = 16; F(2,51) = 25.92, P < 0.0001), pyrocortex 
(26.3 ± 1.4, n = 22 vs. 11.2 ± 1.0, n = 16 vs. 16.1 ± 0.7, n = 16; F(2,51) = 44.4, P < 0.0001), thalamus (29.9 ± 2.4, 
n = 22 vs. 12.5 ± 1.5, n = 16 vs. 20.3 ± 1.5, n = 16; F(2,51) = 19.1, P < 0.0001) and external capsule (39.4 ± 1.9, 
n = 22 vs. 27.0 ± 2.1, n = 16 vs. 22.9 ± 1.4, n = 16; F(2,51) = 21.4, P < 0.0001). Compared to the intense GFP stain-
ing in PBS-injected brains, those injected with either SS-hAFSCs or RS-hAFSCs showed reduced staining inten-
sity, with those injected with SS-hAFSCs showing the strongest decrease (Fig. 4b).
Injection of SS-hAFSCs prevents demyelination in the striatum and external capsule. Neuronal 
myelination was assessed by measuring the intensity of myelin basic protein (MBP) immunostaining in the stria-
tum and external capsule. Results revealed that in PBS-injected brains, the HI insult significantly decreased MBP 
luminosity in the external capsule (43.5 ± 2.3, n = 10 vs. 28.7 ± 1.5, n = 18, P = 0.0007, two-way ANOVA followed 
by Bonferroni’s multiple comparison test), but was not significant in the striatum (38.3 ± 2.1 mean ± SEM, n = 11 
vs. 27.7 ± 1.5, n = 18; P = 0.21) (Fig. 5a). However, injection of SS-hAFSCs tended to prevent demyelination in 
both regions (35.8 ± 6.1, n = 14; P = 0.18 in the striatum and 35.2 ± 2.5, n = 14; P = 0.21 in the external capsule). 
Notably, the injection of RS-hAFSCs did not show any positive effect on myelination in either brain regions 
(25.6 ± 3,4, n = 15; P = 0.99 in the striatum and 26.1 ± 3.4, n = 15; P = 0.99 in the external capsule) (Fig. 5a). 
Immunohistochemistry for MBP confirmed the trend towards prevention of demyelination in the HI brains 
injected with SS-hAFSCs (Fig. 5b).
Figure 3. SS-hAFSCs reduce microglia activation in hippocampus, striatum and pyriform cortex. (a) Microglia 
activation, assessed by αM (CD11b) scoring in contralateral forebrain, showing reduction in the hippocampus, 
striatum and pyriform cortex of HI mice injected injected with SS-hAFSCs compared to brains injected 
with PBS alone without cells (mean ± SEM), **P < 0.01, *< 0.05. (b) Representative images (low and high 
magnification) of CD11b-stained brain sections of HI mice injected with either PBS only, SS-hAFSCs or RS-
hAFSCs.
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Injection of SS-hAFSCs led to a 65% decrease in TGFβ1+ cells. The number of hippocampal 
TGFβ1 + cells was significantly increased in the brains of mice that received an HI insult and were not injected 
(HI) and those who received an HI insult but were injected with PBS alone (PBS), compared to those that did not 
receive any HI insult (naïve) (100.1 ± 10.3, n = 9 vs. 96.9 ± 8.5, n = 17 vs. 40.2 ± 5.7, n = 6; P = 0.003, one-way 
ANOVA followed by Bonferroni’s multiple comparison test). Injection of SS-hAFSCs, but not RS-hAFSCs, led 
to a 65% decrease in TGFβ1+ cells (58.6 ± 8.6, n = 16; P = 0.005 for SS-hAFSCs and 101.6 ± 7.4, n = 15, P > 0.99 
for RS-hAFSCs) (Fig. 6a). Co-immunostaining for TGFβ1 and either CD11b (microglia) or GFAP (astroglia) on 
sections of PBS-injected brains confirmed reduced levels of TGFβ1, CD11b and GFAP levels in SS-hAFSC- trans-
planted mice, as shown in Fig. 6b.
Neuroprotection of the HI mouse brain by SS-AFSCs is likely to be via endoglin-dependent 
inhibition of TGFβ1. We injected 100,000 cells in 2 μl PBS in the contralateral side of the brain and assessed 
the presence of donor cells in the ipsilateral side 48 hours later using an anti-human Nuclear Antigen antibody, 
which reacts with human but not mouse tissue. We found that donor SS-hAFSCs or RS-hAFSCs were absent in 
the ipsilateral side of the brain, suggesting that the beneficial effects observed by donor cells are not mediated via 
direct differentiation but through the release of soluble factors.
Transforming growth factor (TGF) β1 secreted by MSCs has been recently shown to modulate the functional 
properties of microglia, suggesting that TGFβ1 levels may be used as a biological marker to predict the efficacy 
of stem cells to counteract neuro-inflammation15. However, the concentration of TGFβ1 released by SS-hAFSCs 
was not significantly higher than that released by RS-hAFSCs (0.18 ± 0.08, mean ± SD, n = 4 for RS-hAFSCs vs. 
1.16 ± 0.54, n = 4 for SS-hAFSCs, unpaired t-test, P = 0.12) (Fig. 7a). However, endoglin (CD105), a glycopro-
tein that binds TGFβ1 with high affinity and inhibits TGFβ1-smad3 signalling16, was released by SS-hAFSCs 
but not by RS-hAFSCs (66.2 ± 8.2, n = 4 mean ± SD for SS-hAFSCs vs. 0.54 ± 0.3, n = 4 for RS-hAFSCs, t-test, 
P = 0.0002) (Fig. 7b). Together, these results indicate that whilst both SS-hAFSCs and RS-hAFSC secrete TGFβ, 
only SS-hAFSCs secrete endoglin, which may inhibit TGFβ1-smad3 signalling in target cells.
Discussion
Human amniotic fluid, which can be retrieved during caesarean section or at birth, is a valuable source of fetal 
stem cells that can be used without ethical concerns for allogeneic and autologous applications in regenerative 
Figure 4. Both SS-hAFSCs and RS-hAFSCs reduce reactive astrogliosis. (a) Reactive astrogliosis, assessed by 
GFAP staining in contralateral forebrain, showing reduction in all the brain regions of HI mice injected with 
SS-hAFSCs or RS-hAFSCs, compared to PBS-injected brains (mean ± SEM), ***P < 0.0001. (b) Representative 
images (low and high magnification) of GFAP-stained brain sections of HI mice injected with either PBS only, 
SS-hAFSCs or RS-hAFSCs.
www.nature.com/scientificreports/
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medicine. These cells present a higher ability to differentiate and exhibit higher growth kinetics than adult stem 
cells, whilst showing no sign of tumorigenicity3. Despite having been characterised by their plastic-adherence and 
expression of the stem cell surface marker CD117, human amniotic fluid stem cells (hAFSCs) are heterogeneous 
with regards to their morphology. We, and others, have in particular distinguished between cells presenting a 
spindle-shaped (SS-hAFSCs) and round-shaped (RS-hAFSCs) morphology, which show differences with regards 
to their proteomic profile, growth characteristics and differentiation potential7,17. In the present study, we isolated 
and pooled clonal populations of SS-hAFSCs and RS-hAFSCs and showed that both cell types express CD73 but, 
unlike RS-hAFSCs, SS-hAFSCs uniquely co-express CD90 (Thy-1) and CD105 (endoglin). Thy-1 has several 
cellular functions, being involved in cell-cell interactions, regulating apoptotic signalling, modulating prolifer-
ation, survival and cytokine/growth factor response, and promoting T cell activation18. Endoglin is part of the 
TGFβ receptor complex, thus modulating the response to the binding of TGFβ, activin A and BMPs. It plays an 
important role in angiogenesis19. However, there is no evidence that phenotypical differences translate into in vivo 
functional differences. Here, we show that a single injection of SS-hAFSCs into the HI mouse brain immediately 
after the HI insult resulted 48 hours later in a significant reduction of brain lesion size and TUNEL-positive cells. 
Notably, injection of RS-hAFSCs failed to show such neuro-protective effects. Donor cells were absent from the 
site of injury 48 hours after intracranial injection, suggesting they mediate their neuro-repair effects through par-
acrine/endocrine mechanisms. In this study, we pooled together several donor samples, to reduce inter-individual 
differences. Further analysis will be required to develop in vitro screening platforms to compare the therapeutic 
efficacy of individual samples. The HI mouse model used in this study, which is a modification of the Vannucci 
model of unilateral ligation/occlusion of the common carotid artery at postnatal day 7 followed by a period of 
hypoxia, presents some phenotypic similarities to periventricular white matter damage in humans. These sim-
ilarities include prevention of demyelination, ventricular enlargement, loss of neurons, damage to axons and 
dendrites, oligodendrocyte cell death and alterations of oligodendrocyte development, which are the hallmarks 
of brain injury in preterm/term infants20. We are the first to report the heterogeneity of the hAFSC population in 
relation to its neuro-regenerative properties, and to identify a sub-population of CD117+ spindle-shaped cells 
that can be easily isolated and purified based on their spindle-shape morphology and co-expression of CD90 and 
CD105.
In the specific disease model used here, we demonstrated that understanding the mechanistic properties 
of the cells is important to further improve stem cell-based therapy. Specifically, our data show that both cell 
types decreased reactive astrogliosis, indicating that the neuro-protective effects of SS-hAFSCs are not attribut-
able to a reduction in astroglial activation and indeed astrogliosis failed to influence on the extent of HI brain 
injury in neonatal mice20. However, SS-hAFSCs, but not RS-hAFSCs, lowered the levels of astroglial TGFβ1, 
decreased microglia activation and prevented demyelination, suggesting that donor SS-hAFSCs modulated the 
host immune system by decreasing resident TGFβ1 levels, thereby lowering the microglial response to neuronal 
death and restoring the oligodendrocyte/astrocyte differentiation balance. Not surprisingly, further analysis of 
Figure 5. SS-hAFSC injection prevents demyelination in the striatum and external capsule. (a) Myelin Binding 
Protein luminosity in contralateral forebrain, showing increase in the striatum and external capsule of HI mice 
injected with SS-hAFSCs, compared to PBS-injected brains (mean ± SEM), ***P < 0.0001. (b) Representative 
images (low and high magnification) of MBP-stained brain sections of HI mice injected with either PBS only, 
SS-hAFSCs or RS-hAFSCs.
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Figure 6. Hippocampal TGFβ1 levels are reduced in mice transplanted with SS-hAFSCs. (a) Number of 
TGFβ1+ cells (average of three random fields with 200 × magnification) in the hippocampus of naïve mice, HI 
non-transplanted mice, and in the hippocampus of HI mice transplanted with either PBS alone without stem 
cells, SS-hAFSCs and RS-hAFSCs. (mean ± SEM), **P < 0.001. (b) Co-immunostaining for GFAP (green 
staining), TGFβ1 (red staining) and DAPI (blue) and CD11b (green staining), TGFβ1 (red staining) and DAPI 
(blue) in the hippocampus of HI mice transplanted with SS-hAFSCs and PBS only.
Figure 7. Potential mechanism of action of SS-hAFSC in the hypoxic-ischemic mouse brain. (a) TGFβ1 
ELISA demonstrates that both SS-hAFSCs and RS-hAFSCs secrete TGFβ1. (b) Endoglin ELISA demonstrates 
increased levels of secretion in SS-hAFSC compared to RS-hAFSC. **p < 0.01.
www.nature.com/scientificreports/
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the phenotypical differences between SS-hAFSCs and RS-hAFSCs showed that only SS-hAFSCs release endoglin. 
These results indicate that inhibition of the TGFβ1 signaling pathway in target cells may be mediated by the 
release of endoglin.
In conclusion, this study provides the first evidence for the neuro-protective effects of a subset of 
spindle-shaped CD73+ CD90+ CD105+ fetal stem cells that can be easily and ethically isolated from mid-trimester 
amniotic fluid and will provide the basis for the development of innovative stem-cell based therapeutics for the 
protection of the developing brain.
Methods
Ethics statement. The healthy donors who provided the amniotic fluid in this study provided written 
informed consent in accordance with the Declaration of Helsinski. The ethical approval given by the Research 
Ethics Committees of Hammersmith & Queen Charlotte’s Hospitals (2001/6234) in compliance with UK national 
guidelines (Review of the Guidance on the Research Use of Fetuses and Fetal Material (1989), also known as the 
Polkinghorne Guidelines. London: Her Majesty’s Stationery Office, 1989: Cm762) for the collection of fetal tissue 
for research.
All experimental protocols were approved by the UK Home Office guidelines (PPL 70/7173 and 70/8784), and 
The Institutional Licensing Committee of University College London and we followed The ARRIVE guidelines. 
All methods were carried out in accordance with relevant guidelines and regulations.
Cell culture. Human mid-trimester amniotic fluid was collected at mid-gestation from normal pregnancy and 
immediately spun before the cell pellet was resuspended into a single cell suspension in StemMACS MSC expan-
sion media under xeno- and serum-free conditions at low density (102 cells/cm2) onto a plastic culture dish and 
let to expand until clones of >50 cells formed. The clones had a homogeneous morphology, with some clones pre-
senting a round-shaped cytoplasm, whilst others presented a spindle-shaped one. 5–10 clones presenting similar 
morphology were mechanically detached, pooled, spun, resuspended into single cells and plated (104 cells/cm2) 
on plastic culture dishes without feeders in Dulbecco’s modified Eagle’s medium (DMEM-HG) (Invitrogen) sup-
plemented with 10% fetal bovine serum (Biosera), 2 mM L-glutamine, 50 IU/ml penicillin and 50 mg/ml strepto-
mycin (Gibco-BRL) (D10), at 37 °C in a 5% CO2 incubator.
Enzyme-linked immunosorbent assays (ELISAs). Cells were plated at 2 × 104 cells/cm2 in four wells of 
a 6-well plate. 72 hours after seeding, 8 ml conditioned medium was removed and concentrated using an Amicon 
ultra-4 15 ml 3 K NMWL filter by centrifugation at 4000 g for 40 minutes. 300 µl of D10 was then added to the 
concentrated medium and 100 µl of this was added per well of the ELISA plate. The human TGFβ1and endoglin 
ELISA kit (Abcam) were performed according to the manufacturer’s instructions.
Flow cytometry. Cells were detached as described previously and washed in flow buffer (PBS + 1% BSA). 
Cells were then centrifuged at 5000 g for 2 minutes before 1 × 105 cells were resuspended in the appropriate pri-
mary antibody (anti-CD105, anti-CD90, anti-CD73, [All Miltenyi Biotec]) at its optimal dilution (1:10) in flow 
buffer and incubated for 1 hour at 4 °C. For unconjugated antibodies, cells were then washed and resuspended in 
a 1:10 dilution of FITC-conjugated donkey anti-mouse (Jackson ImmunoResearch labs) for 30 minutes at 4 °C. 
Cells were then analysed using a Becton Dickinson FACScalibur flow cytometer (BD bioscience) using Cell Quest 
Pro and FlowJo software.
Immunofluorescence. Cryosections were post-fixed in 4% PFA in Phosphate-Buffered Saline (PBS 1 × pH 
7.6; 5 min, RT), rinsed in PBS, blocked (1 h RT) with PBS supplemented with 1% BSA and 5% Normal Goat 
Serum (NGS) andincubated (overnight, 4 °C) with the primary antibody TGFβ1 (1:200, Abcam ab92486), GFAP 
(1:500, Dako), CD11b (1:500, Serotec) in PBS/BSA, washed (3 times) in PBS/BSA, incubated (1 h RT) with sec-
ondary antibodies in PBS/BSA, washed and rinsed in PBSPBS and mounted inVectaShield containing DAPI 
(Vector Labs) and visualized immediately., Images were collected using a LeicaDM 6000 fluorescence microscope 
(40× PLAN APO objective) and transferred to Adobe Photoshop (Adobe Systems). Secondary antibodies for 
single and double immunofluorescence were: donkey anti-mouse IgG FITC (1:100 dilution; multiple-labelling 
grade; Jackson ImmunoResearch Laboratories) and goat anti-rabbit Alexa-Fluor 594, Thermo Fisher).
Hypoxic-ischemic insult. The animals used were from the C57/BL6 strain (Charles River, Kent, UK). The 
surgical procedures to induce HI insult were performed as previously described21. Briefly, seven-day-old mice were 
anaesthetised with isofluorane (5% induction followed by 1.5% maintenance) before undergoing permanent left 
common carotid artery occlusion with 8/0 polypropylene suture. The mice were left to recover at 36 °C and returned 
to the dam for 2 hours before being placed in a hypoxia chamber and exposed to humidified 8% oxygen /92% 
nitrogen for 1 hour (severe insult). Mice were randomized to receive either 100,000 cells (SS-hAFSCs or 
RS-hAFSCs) in 2 μl PBS or with PBS only (with no cells) via freehand intracranial injection through the skull in 
the brain hemisphere contralateral to the arterial occlusion. The mice were then returned to the dam and sacri-
ficed 48 hours later by intraperitoneal injection of pentobarbitone and perfused with 30 ml 4% paraformaldehyde 
in PBS (intracardiac injection). Mice from at least five different litters were used in each experimental group, and 
mice from each litter were randomly assigned to all experimental groups, taking gender into account in a way that 
both genders were equally distributed among groups.
Tissue sample preparation. Brains were removed straight after perfusion, post-fixed in 4% paraformalde-
hyde in PBS (1 h, 4 °C) and cryopreserved in phosphate-buffered 30% sucrose solution for 24 hours, as previously 
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described21. The brains were then frozen on dry ice, cut on a cryostat into sequential 40 μm sections and stored at 
−80 °C until processed for analysis by an experimenter blinded to the group analysed.
Immunohistochemistry and histological analysis. For each brain, five cryosections (400 μm apart) 
were rehydrated in distilled water and stained using immunohistochemistry. The sections were incubated over-
night with primary antibodies, i.e. CD11b (1:5000, Serotec), GFAP (1:6000, Dako), MBP (1:1000), washed with 
PBS, incubated for 2 hours with biotinylated goat anti-rabbit or anti-rat secondary antibody (1:100, Vector, 
Peterborough, UK), washed with PBS, and incubated with Avidin-Biotinylated horseradish peroxidase Complex 
(Vector) before being visualized with diaminobenzidin/H2O2 (Fisher Scientific, Loughborough, UK). Five fur-
ther 400 μm-interspaced sections from each brain were used for Terminal transferase mediated d-UTP nick 
end labelling (TUNEL) (Roche, Burgess Hill, UK), following the manufacturer’s instructions. Five further 400 
μm-interspaced sections from each brain were used for staining with cresyl violet (Nissl).
Detection of donor cells in the ipsilateral side of the brain was performed 48 hours after injection in the con-
tralateral side using anti-human Nuclear Antigen antibody (Abcam).
Scoring and measurement. The brain infarct volume was measured on Nissl-stained sections, as previ-
ously reported20. Briefly, sections scans were imported into the Optimas 6.5 image analysis software (Bothell, 
WA, USA) and areas of intact staining were outlined and measured bilaterally in cortex, hippocampus, striatum, 
pyriform cortex, thalamus and external capsule. The percentage of tissue loss was the calculated by converting the 
measured areas into square millimetres and converting the volume by multiplying by 400 μm. The sum of these 
volumes was used to calculate the percentage of intact brain tissue as injured/intact volume x 100.
For CD11b (αM integrin) scoring, semi-quantitative scores were allocated to each brain region (cortex, hip-
pocampus, striatum, pyriform cortex, thalamus and external capsule) by an observer blinded to the treatment of 
the groups, as previous described21,23, to describe microglial appearance i.e. 0 (no activation), 1 (focal microglial 
activation), 2 (mild phagocytic activation affecting <50% of the region), 3 (phagocytic activation affecting >50% 
of the region) and 4 (total phagocytic activation).
For TUNEL immunoreactivity, the number of positive cells was counted bilaterally in three different optical 
fields at 20× magnification in cortex, hippocampus, striatum, pyriform cortex, thalamus and external capsule, 
and the counts were averaged per animal and per group.
The intensity of GFAP staining was quantified using optical luminosity values. Images for both ipsilateral and 
contralateral sides of the brain were captured with a Sony AVT-Horn 3CCD colour video camera (24 bit RGB, 
760 × 570 pixel resolution) and three different optical fields in the cortex, hippocampus, striatum, pyriform cor-
tex, thalamus and external capsule, as well as the surrounding glass at x20 magnification. We used Optimas 6.5 
software to obtain the mean and standard deviation (SD) for optical luminosity values (OVL). SD was subtracted 
from the values obtained for the surrounding glass, as previously described22.
Statistical analysis. Statistical analysis was performed using GraphPad 7.0b. Two-way ANOVAs, followed 
by Bonferroni’s multiple comparison post-hoc test, were used to test if there was an interaction between variables 
and obtain p values. One-way ANOVA were used to determine if there was any statistical difference between the 
means of more than two independent groups. Unpaired T-test was used to compare the means of two independ-
ent groups. P < 0.05 was considered significant.
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